Walder Wyss has advised Vaderis Therapeutics. Vaderis Therapeutics, a Swiss clinical-stage biopharmaceutical company, has announced the completion of a USD 152 million Series B financing round....
Vaderis Therapeutics Closes USD 152 Million Series B Financing and Launches Phase 3 Study for Engasertib
TECregen Secures CHF 10 Million in Seed Round for Thymus Regeneration
Walder Wyss has advised TECregen. TECregen, a biotechnology company based in Basel, Switzerland, has raised CHF 10 million through a seed financing round. The company undertook...
Allegria Therapeutics Secures USD 5.1 Million in Seed Extension Funding
Walder Wyss has advised Allegria Therapeutics. Allegria Therapeutics, a biotechnology company based in Basel, Switzerland, has completed a seed extension funding round, raising USD 5.1 million....
AstraZeneca Acquires Swiss Biotech Firm SixPeaks Bio in USD 300 Million Deal
Walder Wyss has advised SixPeaks Bio AG and its shareholders (including Versant Ventures). Lenz & Staehelin has advised AstraZeneca. AstraZeneca has completed the acquisition of Swiss...
Nuclidium AG Secures CHF 79 Million in Series B Financing Round
VISCHER has advised Nuclidium AG. Walder Wyss has advised Angelini Ventures, Kurma Partners, and Wellington Partners as co-lead investors; Dentons has acted for Neva. Nuclidium AG,...
Mosanna Therapeutics Completes USD 80 Million Series A Funding Round
VISCHER has advised Mosanna Therapeutics AG; Walder Wyss advised EQT Life Sciences. Mosanna Therapeutics AG has successfully closed its USD 80 million Series A funding round....
TransPerfect’s Acquisition of Apostroph Group
Walder Wyss advised TransPerfect; the Apostroph Group stakeholders were represented by KPMG, Milbank, Advestra, and Baker McKenzie. TransPerfect, the world’s largest provider of language and AI...
Alentis Therapeutics’ $181.4 Million Series D Financing Round
Walder Wyss advised Alentis Therapeutics on the deal. Honigman advised Catalio Capital Management. Alentis Therapeutics raised $181.4 million in Series D financing, supported by a syndicate...
SixPeaks Bio AG’s $110 Million Series A Financing Round
Walder Wyss advised SixPeaks Bio AG while Lenz & Staehelin acted as Swiss counsel to AstraZeneca. SixPeaks Bio AG has secured USD30 million in Series A...
Nouscom’s €67.5 Million Oversuscribed Series C Financing Round
Walder Wyss advised the investors while VISCHER acted as legal advisor to Nouscom in the transaction. Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized...
Pierre Fabre Laboratories’ Acquisition of Vertical Bio AG
Walder Wyss advised Versant Ventures on this transaction. ierre Fabre Laboratories, the French pharmaceutical and dermo-cosmetic company, announced the acquisition of Vertical Bio AG, a developer...
Alentis Therapeutics’ $105 Million Series C Funding Round
Walder Wyss advises Alentis Therapeutics on the financing. Alentis Therapeutics has announced $105 million in Series C financing. The funding round was led by Jeito Capital...